CRO

QPS Global Clinical Operations Team Aces Enrollment for Global Study of Prostate Cancer Drug and Completes the First Patient in Europe!

QPS has been assisting an international Sponsor to perform a global, late-phase study to investigate the safety, efficacy, and pharmacokinetic behavior of a newly formulated investigational drug in subjects with advanced prostate carcinoma. The original enrollment goal was 133 patients to be enrolled in approximately 18 months. The QPS Global Clinical Operations team enrolled 137 […]

QPS Global Clinical Operations Team Aces Enrollment for Global Study of Prostate Cancer Drug and Completes the First Patient in Europe! Read More »

QPS will create an (LC)-ICP-MS assay to perform the critical elemental analysis in your drug development study

If you need to quantify blood zinc levels, are working on a gadolinium-based MRI contrast agent, or need to measure platinum levels in mouse livers – a QPS-developed (LC)-ICP-MS assay may well be what you need. These assays, validated according to FDA, EMA and ICH guidelines, can quantify levels of most ELEMENTS (such as iron,

QPS will create an (LC)-ICP-MS assay to perform the critical elemental analysis in your drug development study Read More »

Consultation open on revised EMA Guideline on Medicines to treat Alzheimer’s Disease

The European Medicines Agency (EMA) has released a draft guideline revision on the clinical investigation of medicines for the treatment of Alzheimer’s disease and other dementias for a six-month public consultation. The EMA considers dementia a key public health priority and sees early stage intervention and prevention of symptomatic disease as particularly worthy goals. This

Consultation open on revised EMA Guideline on Medicines to treat Alzheimer’s Disease Read More »

Magnesium-Tablet-Form

New ICP-MS Magnesium (Mg) Assays in Human Plasma and Urine added to the QPS Global Assay Database

The role of Mg in human nutrition has recently received renewed interest. Mg dietary intake has been reported to have decreased during the last 100 years in Western countries. For example, in the US it is often below the recommended dietary allowances. Decreased Mg intake and/or low serum Mg have been associated with a number

New ICP-MS Magnesium (Mg) Assays in Human Plasma and Urine added to the QPS Global Assay Database Read More »

See QPS in London at Informa’s Early Clinical Development Conference, 23 – 24 February 2016

On February 23, Professor Zuzana Diamant, MD PhD, Director of Respiratory & Allergy Research at QPS, will talk about Biomarkers in Respiratory Drug Development and personalized medicine at the Informa-sponsored Early Clinical Development conference, Amba Hotel Marble Arch, London. In her lecture, Professor Diamant will cover the following topics: Definition of a valuable biomarker Which

See QPS in London at Informa’s Early Clinical Development Conference, 23 – 24 February 2016 Read More »

Read the QPS Whitepaper on Phase I Site Selection to support EU Registration

Making the right decision about where to conduct Phase I of a clinical trial is crucial. As long as basic EU regulatory requirements are fulfilled, the investigational site may be located anywhere in the world. This paper will walk you through the three key essential considerations for clinical trials intended to support registration in the

Read the QPS Whitepaper on Phase I Site Selection to support EU Registration Read More »

Specialized, Collaborative Clinical Development Services Provide Peace of Mind for Clients

Okay, we’ll admit it: a company telling you about their new brochure seems about as interesting as looking through your Great Uncle’s vacation pictures – for the tenth time. But we can’t help it. We’re really excited about this one! That’s because we’re proud to provide specialized, collaborative Clinical Development services that help us build

Specialized, Collaborative Clinical Development Services Provide Peace of Mind for Clients Read More »

Scroll to Top